These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26126910)

  • 1. Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases.
    Sun L; Yu CY; Mackey LV; Coy DH
    Curr Top Med Chem; 2015; 16(2):133-40. PubMed ID: 26126910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
    Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Gradilone SA; Huang B; Masyuk AI; Hogan MC; Torres VE; Larusso NF
    Hepatology; 2013 Jul; 58(1):409-21. PubMed ID: 23172758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
    van Keimpema L; Nevens F; Vanslembrouck R; van Oijen MG; Hoffmann AL; Dekker HM; de Man RA; Drenth JP
    Gastroenterology; 2009 Nov; 137(5):1661-8.e1-2. PubMed ID: 19646443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-term outcome of patients with polycystic liver disease treated with lanreotide.
    Chrispijn M; Nevens F; Gevers TJ; Vanslembrouck R; van Oijen MG; Coudyzer W; Hoffmann AL; Dekker HM; de Man RA; van Keimpema L; Drenth JP
    Aliment Pharmacol Ther; 2012 Jan; 35(2):266-74. PubMed ID: 22111942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
    Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
    Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.
    Gevers TJ; Chrispijn M; Wetzels JF; Drenth JP
    BMC Nephrol; 2012 Apr; 13():17. PubMed ID: 22475206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.
    Gevers TJ; Inthout J; Caroli A; Ruggenenti P; Hogan MC; Torres VE; Nevens F; Drenth JP
    Gastroenterology; 2013 Aug; 145(2):357-65.e1-2. PubMed ID: 23665274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin and its Analogs.
    Sun L; Coy DH
    Curr Drug Targets; 2016; 17(5):529-37. PubMed ID: 26951062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials.
    Suwabe T; Barrera FJ; Rodriguez-Gutierrez R; Ubara Y; Hogan MC
    PLoS One; 2021; 16(9):e0257606. PubMed ID: 34559824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.
    Gevers TJ; Nevens F; Torres VE; Hogan MC; Drenth JP
    Liver Int; 2016 Apr; 36(4):595-602. PubMed ID: 26481454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
    van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH;
    Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum bile acids associate with liver volume in polycystic liver disease and decrease upon treatment with lanreotide.
    Dekker SEI; Bierau J; Giera M; Blomberg N; Drenth JPH; Mayboroda OA; de Fijter JW; Soonawala D;
    Eur J Clin Invest; 2024 Apr; 54(4):e14147. PubMed ID: 38071418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
    Hogan MC; Chamberlin JA; Vaughan LE; Waits AL; Banks C; Leistikow K; Oftsie T; Madsen C; Edwards M; Glockner J; Kremers WK; Harris PC; LaRusso NF; Torres VE; Masyuk TV
    Clin J Am Soc Nephrol; 2020 Sep; 15(9):1267-1278. PubMed ID: 32843370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.
    Masyuk TV; Masyuk AI; Lorenzo Pisarello M; Howard BN; Huang BQ; Lee PY; Fung X; Sergienko E; Ardecky RJ; Chung TDY; Pinkerton AB; LaRusso NF
    Hepatology; 2017 Oct; 66(4):1197-1218. PubMed ID: 28543567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin analogues reduce liver volume in polycystic liver disease.
    van Keimpema L; de Man RA; Drenth JP
    Gut; 2008 Sep; 57(9):1338-9. PubMed ID: 18719151
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic Targets in Polycystic Liver Disease.
    Masyuk TV; Masyuk AI; LaRusso NF
    Curr Drug Targets; 2017; 18(8):950-957. PubMed ID: 25915482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin analogues for treatment of polycystic liver disease.
    Gevers TJ; Drenth JP
    Curr Opin Gastroenterol; 2011 May; 27(3):294-300. PubMed ID: 21191289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into targeting hepatic cystogenesis in autosomal dominant polycystic liver and kidney disease.
    Barten TRM; Bernts LHP; Drenth JPH; Gevers TJG
    Expert Opin Ther Targets; 2020 Jun; 24(6):589-599. PubMed ID: 32250187
    [No Abstract]   [Full Text] [Related]  

  • 19. Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease.
    Temmerman F; Ho TA; Vanslembrouck R; Coudyzer W; Billen J; Dobbels F; van Pelt J; Bammens B; Pirson Y; Nevens F
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2353-9.e1. PubMed ID: 26073493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin analogs - from new molecules to new applications.
    Pawlikowski M; Mełeń-Mucha G
    Curr Opin Pharmacol; 2004 Dec; 4(6):608-13. PubMed ID: 15525552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.